|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Moexipril#Patient Counseling Information]] |
| {{Moexipril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==Information for Patients==
| |
| | |
| ====Food====
| |
| | |
| Patients should be advised to take Moexipril HCl and [[Hydrochlorothiazide]] Tablets one hour before a meal.
| |
| | |
| Angioedema
| |
| | |
| [[Angioedema]], including laryngeal edema, may occur with treatment with ACE inhibitors, usually occurring early in therapy (within the first month). Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of the face, extremities, eyes, lips, tongue, difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician. | |
| | |
| ====Symptomatic Hypotension====
| |
| | |
| Patients should be cautioned that [[lightheadedness]] can occur with Moexipril HCl and [[Hydrochlorothiazide]] Tablets, especially during the first few days of therapy. If fainting occurs, the patient should stop taking Moexipril HCl and Hydrochlorothiazide Tablets and consult the prescribing physician.
| |
| | |
| All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult their physician if they develop these conditions.
| |
| | |
| ====Hyperkalemia====
| |
| | |
| Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting their physician.
| |
| | |
| ====Neutropenia====
| |
| | |
| Patients should be told to report promptly any indication of infection (e.g., [[sore throat]], [[fever]]) that could be a sign of [[neutropenia]].
| |
| | |
| ====Pregnancy====
| |
| | |
| Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors and should also be told that these consequences do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. Patients should be asked to report pregnancies to their physicians as soon as possible.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLET, COATED [PADDOCK LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c657e39-edeb-4fa1-9a67-78eed3702494 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |